SlideShare ist ein Scribd-Unternehmen logo
1 von 49
Downloaden Sie, um offline zu lesen
Anti-Retroviral Agents (ARVs)
BY; SEYOUM GIZACHEW (B.Pharm., MSc)
Anti-Retroviral Agents (ARVs)

HIV-1 Virology

2
The HIV Epidemic Unfolds
• Sudden outbreak in USA of opportunistic infections and
cancers in homosexual men in 1981.
– Pneumocystis carinii pneumonia (PCP), Kaposi’s
sarcoma, and non-Hodgkins lymphoma
• HIV isolated in 1984 - Luc Montanier (Pasteur Institute,
Paris) and Robert Gallo (NIH, Bethesda, USA)
• HIV diagnostic tests developed in 1985.
• First antiretroviral drug, zidovudine, developed in 1986
• Exploding pandemic.
– Has infected more than 50 million people around the
world
– Has killed over 22 million people.
3
Classification of HIV
• Retrovirus: single stranded RNA transcribed to double
stranded DNA by reverse transcriptase
• Integrates into host genome
• Can lie dormant within a cell for many years, especially in
resting (memory) CD4+ T4 lymphocytes
• HIV type (distinguished genetically)
– HIV-1 -> worldwide pandemic (~ 40 M people)
– HIV-2 -> isolated in West Africa; causes AIDS much more
slowly than HIV-1 but otherwise clinically similar.

4
5
6
How HIV Enters Cells
• There are three crucial steps for entry of HIV into the CD4 T
cell:
1.Binding of HIV via the gp120 envelope protein to the CD4
receptor (attachment),
2.Binding to coreceptors via conformational changes to
gp120, and finally
3.Fusion of virus and cell
• In addition to the CD4 receptor, HIV requires coreceptors for
entry into the target cell.
• The two most important ones are CXCR4 and CCR5.
• HIV variants mainly using CCR5 are referred to as R5
viruses; those using CXCR4 are referred to as X4 viruses.
7
How HIV Enters Cells cont…
• When the virus enters the blood, it binds a protein on its
surface (gp120) to a CD4 receptor and co-receptors (CXCR4
or CCR5) on the CD4 cell.
• Then gp120 shifts to expose gp41.
• Once exposed, gp41 pierces the CD4 cell and pulls it in close
enough to allow viral-cell fusion.
• Binding of virus to cell surface results in fusion of viral
envelope with cell membrane.
• Viral core is released into cell cytoplasm.

8
HIV and Cellular Receptors

9
Viral-host Dynamics
• About 1010 (10 billion) virions are produced daily
• Average life-span of an HIV virion in plasma is ~6 hours
• Average life-span of an HIV-infected CD4 lymphocytes is
~1.6 days
• HIV can lie dormant within a cell for many years,
especially in resting (memory) CD4 cells, unlike other
retroviruses.
• The extremely high rates of viral replication results in every
possible point mutation in the viral genome arising daily.
• In any given patient, the virus usually varies by 1-6% in the
env gene, for example.

10
11
HIV Life Cycle and Sites for Therapeutic Intervention

12
Classes of Antiretrovirals
• Fusion inhibitors
– Prevents fusion of the virus into a CD4 cell by preventing
conformational change needed to allow virus to enter a
CD4 cell
• Nucleoside reverse transcriptase inhibitors (NRTIs) or nukes
(zidovudine, lamivudine)
– Mimic naturally occurring nucleosides
– Blocks viral DNA construction as they deceive reverse
transcriptase.
• Non- nucleoside reverse transcriptase inhibitors (NNRTIs) or
non-nukes (Nevirapine, Efavirenz)
– Bind to the reverse transcriptase enzyme
• Protease inhibitors (PIs) (Indinavir, lopinavir)
– Prevents cleavage of precursor protein chains.
13
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
(NRTI’s)
•
•
•
•
•
•
•
•

Lamivudine (3TC)
Stavudine (d4T)
Zidovudine (ZDV, AZT)
Didanosine (ddI)
Tenofovir (TDF)
Abacavir(ABC)
Emtricitabine(FTC)
Zalcitabine(DDC)

14
NRTI Mechanism of Action
• NRTIs must first undergo intracellular phosphorylation to
be active.
• NRTIs inhibit the viral reverse transcriptase enzyme
– Enzyme responsible for transcribing viral RNA into
double stranded DNA
• NRTIs mimic other nucleosides and are incorporated into the
DNA strand
• They prevent the addition of the natural nucleosides into the
DNA strand
• This halts the production of new virions

15
NRTI Class Side Effects
•
•
•
•
•
•

Nausea
Headache
Peripheral Neuropathy (DDC > d4T/ddI)
Lipoatrophy
Pancreatitis (ddI > d4T)
Lactic Acidosis
– d4T > ddI > ZDV
– Rare with ABC, TDF, 3TC and FTC

16
Zidovudine (ZDV)
•
•
•
•
•

•
•
•

It is a deoxythymidine analog.
Phosphorylated by cellular thymidine kinase.
incorporated into DNA chain and terminates synthesis.
well absorbed from the gut and distributed to most body
tissues and fluids, including the cerebrospinal fluid
The most common adverse effect is myelosuppression,
resulting in macrocytic anemia.
Food decreases ZDV-related nausea
Pregnancy: category C
Advocated for pregnant women beyond first trimester to
prevent vertical transmission.

17
Zidovudine (ZDV) cont…
• Elimination: Metabolized by liver to 5’-glucuronyl
zidovudine, which is renally excreted.
– Reduce dose with renal or hepatic compromise:
• Drug Interactions: ZDV and D4T compete for activation by
thymidine kinase.
• Combinations containing AZT plus d4T, is therefore
pointless, since both drugs would compete for the same
bases.
• The combination of these drugs is antagonistic in vitro and in
vivo: do not use together.

18
Zidovudine (ZDV) cont…
• Toxicity
– Nausea
– Bone Marrow Suppression
• Anemia (fatigue)
• Granulocytopenia (low platelet count)
• Neutropenia (low white blood cell [neutrophils] count)
– Headaches
– Myalgia
– Myopathy
– Insomnia
– Pigmentation of nail beds
– Lactic acidosis
19
Lamivudine (3TC)
• A synthetic nucleoside (cytidine) analogue reverse
transcriptase inhibitor
• Active against HIV-1, HIV-2, and hepatitis B virus.
• Phosphorylated 3 times by thymidine kinase to the active
metabolite, 3TC-triphosphate.
• Competes with deoxycytidine triphosphate (dCTP) for
binding to reverse transcriptase and incorporation of the
nucleoside analogue into viral DNA results in the
termination.
• 3TC-TP is a weak inhibitor of mammalian DNA polymerases
α, β, and γ.
• Bioavailability (F): 86%.
20
Lamivudine (3TC) cont…
• CSF Levels: 13% of serum levels (these levels have been
shown to clear HIV RNA from CSF)
• T1/2: 3-6 hours
• Intracellular T1/2: 12 hours
• Pregnancy: (Category C)
– Crosses placenta.
– Use in pregnancy is safe and well established, and
effective.
– When combined with Zidovudine, efficacy in preventing
perinatal transmission is also well established.
• rapid development of resistance, and a single point mutation
on RT gene.
21
Lamivudine (3TC) cont…
• Intracellular T1/2
– NRTIs work in the cell, duration of action is based on
intracellular half-life.
• Toxicity: very rare
– Headache
– Occasional nausea
– Lactic acidosis

22
Tenofovir Disoproxil Fumarate (TDF)
• TDF is different from nucleosides in that it has already been
phosphorylated once.
• T1/2: 12 to 18 hours
• Intracellular T1/2: 10 to 50 hours
• Pregnancy: (Category B) Crosses placenta.
• Bioavailability improves with food, especially high-fat meal.
• Primarily eliminated by a combination of glomerular
filtration and active renal tubular secretion.
• Toxicity
– Headache, Nausea, diarrhea
– Lactic acidosis, fatty liver
– Renal insufficiency (rare)
23
NRTI Mitochondrial Toxicity
• Inhibition of mitochondrial DNA polymerase– oxidative metabolism,
– ATP generation
• Implicated in lactic acidosis
• Other possible manifestations:
– Neuropathy (d4T, ddI)
– Lipoatrophy (d4T)
– Pancreatitis (ddI)
– Myopathy (ZDV)
– Cardiomyopathy (d4T, ZDV)

24
Facial Lipoatrophy: may be due mitochondrial toxicity.
Not reversible, occur commonly with stavudine

Facial Lipoatrophy:

25
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
• Nevirapine (NVP)
• Efavirenz (EFV)
• Delavirdine (DLV)

• Etravirine

26
NNRTI Mechanism of Action

27
NNRTI Mechanism of Action cont…
• NNRTIs also inhibit the viral reverse transcriptase enzyme
but have a different mechanism of action compared to
NRTIs.
• NNRTIs bind directly to the reverse transcriptase enzyme.
– Inhibit viral DNA synthesis.
• Unlike the NRTI agents, NNRTIs neither compete with
nucleoside triphosphates nor require phosphorylation to be
active.
• All are substrates for CYP3A4 and can act as inducers
(nevirapine), inhibitors (delavirdine), or mixed inducers and
inhibitors (efavirenz).

28
Efavirenz
• Should be taken on an empty stomach because high-fat meal
increase toxicity
• metabolized by CYP3A4 and CYP2B6 to inactive
metabolites
• It is highly bound to albumin (~ 99%)
• The principal adverse effects: dizziness, drowsiness,
insomnia, headache, confusion, amnesia, agitation, delusions,
depression, nightmares, euphoria and Skin rash
• It is both inducer and an inhibitor of CYP3A4.
• Contraindicated in pregnancy (1st trimester)!!
– Known to cause birth defects

29
Nevirapine
• oral bioavailability (90%) is not food-dependent
• It is extensively metabolized by the CYP3A isoform
• When initiating therapy, gradual dose escalation over 14 days
is recommended to decrease the incidence of rash
• Hepatotoxicity occurs in about 4% of patients.
• a moderate inducer of CYP3A metabolism.
• Rash occurs in approximately 17% of patients

30
Nevirapine: Moderate Rash

31
Nevirapine: Severe Rash

32
Protease Inhibitors (PIs)
•
•
•
•
•
•
•
•
•
•

Lopinavir
Nelfinavir
Indinavir
Saquinavir
Ritonavir
Amprenavir
Atazanavir
Fosamprenavir
Tipranavir
Darunavir

33
Protease Inhibitors (PIs) cont…
• Protease inhibitors
– prevent viral protease enzyme from cleaving the
polyprotein precursor to viral coat protein and reduces
activation of critical viral proteins/enzymes.
• Thus new virons are formed, but are defective and cannot
infect other cells.
• Use of PIs is associated with a syndrome of redistribution
and accumulation of body fat that results in central obesity to
the exception of atazanavir.

34
PI Mechanism of Action

35
PI Mechanism of Action
• Protease enzyme
– responsible for cleaving (cutting up) larger polyproteins
into structural proteins and reverse transcriptase enzyme.
• Protease is needed to form a fully mature, functional virus
that is able to replicate and produce more virus
• Protease inhibitors prevent this enzyme from doing its job in
the later steps of the viral life cycle

36
PI Class Side Effects
• Metabolic Disorders
– Hepatotoxicities
– Hyperglycemia, insulin resistance
– Lipid abnormalities
– Fat redistribution
• Bone Disorders
• GI intolerance
• Drug interactions
• CYP450 3A4 Inhibition
– RTV > IDV = NFV = APV >SQV

37
Lopinavir/Ritonavir
• Combination in which subtherapeutic doses of ritonavir
inhibit the CYP3A4-mediated metabolism of lopinavir.
• Ritonavir is acting as a pharmacokinetic enhancer rather
than an antiretroviral agent.
• Absorption of lopinavir is enhanced with food
• Lopinavir is extensively metabolized by the CYP3A isozyme.
• Toxicity
– Nausea,
– diarrhea
– Lipid abnormalities
– Hyperglycemia
38
Ritonavir
• an inhibitor of HIV-1 and HIV-2 proteases
• Metabolized by 3A4 > 2D6
• Ritonavir potent inhibitor of liver enzymes, especially CYP450 3A4.
– CYP3A4 inhibitory properties exploited to prolong the half-life of
more potent and less toxic PI agents.
• Ritonavir is rarely used as a single PI anymore b/c of its side effect
profile.
• Instead, it is more often combined with other PIs to take advantage of
its pharmacokinetic inhibitory properties.
• Toxicity
– GI intolerance
– Tingling around mouth, bitter taste in mouth
– Hepatitis, use with caution in hepatic impairment
– Lipodystrophy, lipid abnormalities
39
Fat redistribution

“Buffalo Hump”
Central Obesity

40
Fat redistribution

Lipoatrophy
41
Fusion Inhibitors
• Include: Enfuvirtide
• Inhibits entry of HIV into the CD4 cell.
• binds to glycoprotein gp41 (a protein on the viral membrane).
– prevents a change in the shape of the membrane protein
and prevents fusion of the virus and the CD4 cell
membrane.
– blocks entry into the cell
• A synthetic 36-amino-acid peptide
• Unfortunately, Enfuvirtide is only active when injected
subcutaneously.
• This aspect (in addition to its high cost) severely limits its
use in the correctional setting.
• Enfuvirtide lacks cross-resistance to the other currently
approved antiretroviral drug classes.
42
Maraviroc
• First in new class of agents, CCR5 inhibitors
• Approved August 6th, 2007
• Maraviroc binds to the CCR5 receptor on the membrane of human
cells such as CD4 cells.
– prevents the interaction of HIV-1 gp120 and human CCR5
which is necessary for entry into the cell.
• Does not prevent HIV-1 entry into CXCR4-tropic or dual-tropic
cells.
• Indicated (in combination with other ARVs) treatment-experienced
adult HIV-infected patients
• Not recommended in patients who have dual/mixed tropic or
CXCR4-tropic virus
• Use of maraviroc should be based on treatment history and
tropism assay results.
43
Intergrase Inhibitors:
Raltegravir
• A pyrimidinone analog that binds and inhibits the enzyme
integrase.
– It inhibits strand transfer,
• Bioavailability does not appear to be food-dependent
• Metabolized by glucuronidation.

44
Ethiopian ARV Guidelines (2008) - First-line Regimens
Recommended ARV Regimens for Adults and Adolescents:
Preferred :
TDF+FTC/3TC+EFV = Triple FDC
ZDV+3TC+EFV = ZDV/3TC + EFV
ZDV+3TC+NVP = Triple FDC
Alternatives:
D4T/3TC/EFV = Double FDC (d4T/3TC) + EFV
TDF/3TC/NVP
D4T/3TC/NVP = Triple FDC
ABC/3TC/EFV
ABC/3TC/NVP
ABC/3TC/ZDV = ZDV/3TC + ABC
45
Second-line Regimens Recommended ARV Regimens
for Adults and Adolescents:
First-line Regimen

Second-line Regimen

TDF+FTC/3TC+EFV/NVP

ZDV+3TC+LPV/r/ATV/r or
ZDV+ABC+LPV/r/ATV/r

d4T+3TC+EFV/NVP

TDF+3TC+/-ZDV+LPV/r/ATV/r
or
ABC+ ddI+ LPV/r/ATV/r

ABC + 3TC + ZDV

EFV/NVP + LPV/r/ATV/r

46
PMTCT
ARVs decrease risk of MTCT by two mechanisms:
1. By reducing the viral load in the mother
ARVs block viral replication →↓Viral load in the
body→↑CD4cells →Improved maternal immunity
2. By preventing the virus from fixing itself in the infant

47
Table: Three options for PMTCT programmes (WHO 2012)

a

Recommended in WHO 2010 PMTCT guidelines
b True only for EFV-based first-line ART; NVP-based ART not recommended for prophylaxis (CD4 >350)
c Formal recommendations for Option B+ have not been made, but presumably ART would start at
48
diagnosis.
Reading Assignments
• Chemotherapy of protozoal
infections
• Antifungals
• Anthelmintics

49

Más contenido relacionado

Was ist angesagt?

Antiretrovirals
AntiretroviralsAntiretrovirals
Antiretroviralsshabeel pn
 
Anti HIV and antimycobacteial agents
Anti HIV and antimycobacteial agentsAnti HIV and antimycobacteial agents
Anti HIV and antimycobacteial agentsAkshadaShalgaonkar1
 
Navirapine drug
Navirapine drugNavirapine drug
Navirapine drugMadishNiaz
 
rugs, Mechanism Of Action, Adverse Effects, 2007
rugs, Mechanism Of Action, Adverse Effects, 2007rugs, Mechanism Of Action, Adverse Effects, 2007
rugs, Mechanism Of Action, Adverse Effects, 2007Flavio Guzmán
 
Recent Advances in Antiretroviral Therapy
Recent Advances in Antiretroviral TherapyRecent Advances in Antiretroviral Therapy
Recent Advances in Antiretroviral TherapyHtet Wai Moe
 
Pharmacology of antiretrovirals
Pharmacology      of  antiretroviralsPharmacology      of  antiretrovirals
Pharmacology of antiretroviralsDhananjay Desai
 
hiv and new category of anti hiv drugs in clinical trial
hiv and new category of anti hiv drugs in clinical trialhiv and new category of anti hiv drugs in clinical trial
hiv and new category of anti hiv drugs in clinical trialARUP SAHA
 
Antiretroviral therapy _drugs,_mechanism_of_action,_adverse_effects,_2007
Antiretroviral therapy _drugs,_mechanism_of_action,_adverse_effects,_2007Antiretroviral therapy _drugs,_mechanism_of_action,_adverse_effects,_2007
Antiretroviral therapy _drugs,_mechanism_of_action,_adverse_effects,_2007Ndarukwa Pisirai
 
Changing Anti-Retroviral Therapy
Changing Anti-Retroviral TherapyChanging Anti-Retroviral Therapy
Changing Anti-Retroviral Therapyshabeel pn
 
Anti viral drugs presentation
Anti viral drugs presentation Anti viral drugs presentation
Anti viral drugs presentation Abdi Qani Yuusuf
 

Was ist angesagt? (20)

Antiretroviral drugs
Antiretroviral drugsAntiretroviral drugs
Antiretroviral drugs
 
Antiretrovirals
AntiretroviralsAntiretrovirals
Antiretrovirals
 
Anti HIV and antimycobacteial agents
Anti HIV and antimycobacteial agentsAnti HIV and antimycobacteial agents
Anti HIV and antimycobacteial agents
 
Navirapine drug
Navirapine drugNavirapine drug
Navirapine drug
 
Protease inhibitors
Protease inhibitorsProtease inhibitors
Protease inhibitors
 
rugs, Mechanism Of Action, Adverse Effects, 2007
rugs, Mechanism Of Action, Adverse Effects, 2007rugs, Mechanism Of Action, Adverse Effects, 2007
rugs, Mechanism Of Action, Adverse Effects, 2007
 
Recent Advances in Antiretroviral Therapy
Recent Advances in Antiretroviral TherapyRecent Advances in Antiretroviral Therapy
Recent Advances in Antiretroviral Therapy
 
Pharmacology of antiretrovirals
Pharmacology      of  antiretroviralsPharmacology      of  antiretrovirals
Pharmacology of antiretrovirals
 
Antiviral agents 2
Antiviral agents 2Antiviral agents 2
Antiviral agents 2
 
hiv and new category of anti hiv drugs in clinical trial
hiv and new category of anti hiv drugs in clinical trialhiv and new category of anti hiv drugs in clinical trial
hiv and new category of anti hiv drugs in clinical trial
 
Zidovudine
ZidovudineZidovudine
Zidovudine
 
Anti HIV drugs part 2
Anti HIV drugs part 2Anti HIV drugs part 2
Anti HIV drugs part 2
 
Antiretroviral therapy _drugs,_mechanism_of_action,_adverse_effects,_2007
Antiretroviral therapy _drugs,_mechanism_of_action,_adverse_effects,_2007Antiretroviral therapy _drugs,_mechanism_of_action,_adverse_effects,_2007
Antiretroviral therapy _drugs,_mechanism_of_action,_adverse_effects,_2007
 
Changing Anti-Retroviral Therapy
Changing Anti-Retroviral TherapyChanging Anti-Retroviral Therapy
Changing Anti-Retroviral Therapy
 
Chemotherapy of hiv
Chemotherapy of hivChemotherapy of hiv
Chemotherapy of hiv
 
Anti viral agents
Anti viral agentsAnti viral agents
Anti viral agents
 
Anti viral drugs presentation
Anti viral drugs presentation Anti viral drugs presentation
Anti viral drugs presentation
 
Antiviral Drugs ppt
Antiviral Drugs pptAntiviral Drugs ppt
Antiviral Drugs ppt
 
Antiviral Drugs
Antiviral DrugsAntiviral Drugs
Antiviral Drugs
 
Antiviral Drugs
Antiviral DrugsAntiviral Drugs
Antiviral Drugs
 

Ähnlich wie Anti retroviral agents (ar vs) for midwives

Antiviral Agents
Antiviral Agents Antiviral Agents
Antiviral Agents Dr Htet
 
anti- retroviral drugs.pptx
anti- retroviral drugs.pptxanti- retroviral drugs.pptx
anti- retroviral drugs.pptxMONIKA325654
 
Antiretroviral agents pharmacology drugs.pdf
Antiretroviral agents pharmacology drugs.pdfAntiretroviral agents pharmacology drugs.pdf
Antiretroviral agents pharmacology drugs.pdfKushagraPawar5
 
Pharmacotherapy of HIV management
Pharmacotherapy of HIV managementPharmacotherapy of HIV management
Pharmacotherapy of HIV managementsouravpharma
 
Anti retroviral drugs
Anti retroviral drugsAnti retroviral drugs
Anti retroviral drugsRajan Negi
 
anti viral agents sss.pptx
anti viral agents sss.pptxanti viral agents sss.pptx
anti viral agents sss.pptxRmyRmsh
 
HIV (human immunodeficiency virus)
HIV (human immunodeficiency virus)HIV (human immunodeficiency virus)
HIV (human immunodeficiency virus)Aakankshayadav16
 
HIV AND AIDS TREATMENT 2015
HIV AND AIDS TREATMENT 2015HIV AND AIDS TREATMENT 2015
HIV AND AIDS TREATMENT 2015Kasarla Ramesh
 
hiv infection.pptx
hiv infection.pptxhiv infection.pptx
hiv infection.pptxJohnmvula3
 
pathogensis of HIV.pptx
pathogensis of HIV.pptxpathogensis of HIV.pptx
pathogensis of HIV.pptxDigambarShete
 
ANTIRETROVIRAL THERAPY.pptx
ANTIRETROVIRAL THERAPY.pptxANTIRETROVIRAL THERAPY.pptx
ANTIRETROVIRAL THERAPY.pptxSabeeha6
 
PCP 023- Common Communicable Diseases.pptx
PCP 023- Common Communicable Diseases.pptxPCP 023- Common Communicable Diseases.pptx
PCP 023- Common Communicable Diseases.pptxJAsonba2
 
HIV AND ITS OCULAR MANIFESTATION.pptx
HIV AND ITS OCULAR MANIFESTATION.pptxHIV AND ITS OCULAR MANIFESTATION.pptx
HIV AND ITS OCULAR MANIFESTATION.pptxChowdhary2
 

Ähnlich wie Anti retroviral agents (ar vs) for midwives (20)

13. anti retroviral
13. anti retroviral13. anti retroviral
13. anti retroviral
 
Antiviral Agents
Antiviral Agents Antiviral Agents
Antiviral Agents
 
anti- retroviral drugs.pptx
anti- retroviral drugs.pptxanti- retroviral drugs.pptx
anti- retroviral drugs.pptx
 
Antiretroviral agents pharmacology drugs.pdf
Antiretroviral agents pharmacology drugs.pdfAntiretroviral agents pharmacology drugs.pdf
Antiretroviral agents pharmacology drugs.pdf
 
Pharmacotherapy of HIV management
Pharmacotherapy of HIV managementPharmacotherapy of HIV management
Pharmacotherapy of HIV management
 
Anti retroviral drugs
Anti retroviral drugsAnti retroviral drugs
Anti retroviral drugs
 
anti viral agents sss.pptx
anti viral agents sss.pptxanti viral agents sss.pptx
anti viral agents sss.pptx
 
HIV (human immunodeficiency virus)
HIV (human immunodeficiency virus)HIV (human immunodeficiency virus)
HIV (human immunodeficiency virus)
 
HIV AND AIDS TREATMENT 2015
HIV AND AIDS TREATMENT 2015HIV AND AIDS TREATMENT 2015
HIV AND AIDS TREATMENT 2015
 
Analgesia
AnalgesiaAnalgesia
Analgesia
 
hiv infection.pptx
hiv infection.pptxhiv infection.pptx
hiv infection.pptx
 
pathogensis of HIV.pptx
pathogensis of HIV.pptxpathogensis of HIV.pptx
pathogensis of HIV.pptx
 
Mayank.pptx
Mayank.pptxMayank.pptx
Mayank.pptx
 
ANTIRETROVIRAL THERAPY.pptx
ANTIRETROVIRAL THERAPY.pptxANTIRETROVIRAL THERAPY.pptx
ANTIRETROVIRAL THERAPY.pptx
 
AIDS
AIDSAIDS
AIDS
 
AIDS
AIDS AIDS
AIDS
 
PCP 023- Common Communicable Diseases.pptx
PCP 023- Common Communicable Diseases.pptxPCP 023- Common Communicable Diseases.pptx
PCP 023- Common Communicable Diseases.pptx
 
4_5918209357564084424.ppt
4_5918209357564084424.ppt4_5918209357564084424.ppt
4_5918209357564084424.ppt
 
HIV AND ITS OCULAR MANIFESTATION.pptx
HIV AND ITS OCULAR MANIFESTATION.pptxHIV AND ITS OCULAR MANIFESTATION.pptx
HIV AND ITS OCULAR MANIFESTATION.pptx
 
M01 S04 L07 ART Roxas
M01 S04 L07 ART RoxasM01 S04 L07 ART Roxas
M01 S04 L07 ART Roxas
 

Mehr von Mesfin Mulugeta (20)

2nd quarter report 2007 revised
2nd quarter report 2007 revised2nd quarter report 2007 revised
2nd quarter report 2007 revised
 
Outbreak invest. last
Outbreak invest. lastOutbreak invest. last
Outbreak invest. last
 
Evaluation of evidence [compatibility mode]
Evaluation of evidence [compatibility mode]Evaluation of evidence [compatibility mode]
Evaluation of evidence [compatibility mode]
 
Meas.association [compatibility mode]
Meas.association [compatibility mode]Meas.association [compatibility mode]
Meas.association [compatibility mode]
 
5.1
5.15.1
5.1
 
4
44
4
 
3
33
3
 
2
22
2
 
1
11
1
 
Maternity 2013
Maternity 2013Maternity 2013
Maternity 2013
 
Lunch
LunchLunch
Lunch
 
Jokes
JokesJokes
Jokes
 
Jokebox
JokeboxJokebox
Jokebox
 
Obs.mx guideline jush body
Obs.mx guideline jush bodyObs.mx guideline jush body
Obs.mx guideline jush body
 
Ob
ObOb
Ob
 
Ip ppt
Ip pptIp ppt
Ip ppt
 
Bifocals 2
Bifocals 2Bifocals 2
Bifocals 2
 
Bifocals 1
Bifocals 1Bifocals 1
Bifocals 1
 
Bifocals 4
Bifocals 4Bifocals 4
Bifocals 4
 
The da vinci code
The da vinci codeThe da vinci code
The da vinci code
 

Último

SGK VIÊM KHỚP DẠNG THẤP YHN .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN              .pdfSGK VIÊM KHỚP DẠNG THẤP YHN              .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN .pdfHongBiThi1
 
airway management recorded for S2.pptx
airway management  recorded  for S2.pptxairway management  recorded  for S2.pptx
airway management recorded for S2.pptxnakera38
 
Ayurveda research in Hypothyroidism, P
Ayurveda  research  in Hypothyroidism, PAyurveda  research  in Hypothyroidism, P
Ayurveda research in Hypothyroidism, PDr.Shalu Jain
 
Basic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisBasic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisAshishMaletha2
 
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptxRajendra Dev Bhatt
 
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfSGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfHongBiThi1
 
clean rooms and its classification .pptx
clean rooms and its classification .pptxclean rooms and its classification .pptx
clean rooms and its classification .pptxushakiranmai4
 
Spinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptxSpinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptxsiddharthroy26587
 
Reproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptxReproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptxVeereshDemashetti
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptKavitha Krishnan
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptxtusharchokshi1
 
Thyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersThyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersSai Sailesh Kumar Goothy
 
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY  pptxHERPES SIMPLEX VIRUS 12032019 TUESDAY  pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptxPulkitMittal54
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionZeinabEmad3
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)chahattyagi200
 
Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Ahmad Thanin
 
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Dr. Dheeraj Kumar
 
SMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxSMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxAbdirahmanWaseem
 

Último (20)

SGK VIÊM KHỚP DẠNG THẤP YHN .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN              .pdfSGK VIÊM KHỚP DẠNG THẤP YHN              .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN .pdf
 
airway management recorded for S2.pptx
airway management  recorded  for S2.pptxairway management  recorded  for S2.pptx
airway management recorded for S2.pptx
 
Ayurveda research in Hypothyroidism, P
Ayurveda  research  in Hypothyroidism, PAyurveda  research  in Hypothyroidism, P
Ayurveda research in Hypothyroidism, P
 
Basic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisBasic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth Analysis
 
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
 
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfSGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
 
clean rooms and its classification .pptx
clean rooms and its classification .pptxclean rooms and its classification .pptx
clean rooms and its classification .pptx
 
Spinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptxSpinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptx
 
Reproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptxReproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptx
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
 
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptx
 
Thyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersThyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disorders
 
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY  pptxHERPES SIMPLEX VIRUS 12032019 TUESDAY  pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), Addiction
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)
 
Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)
 
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
 
Oral disorders .pptx
Oral disorders .pptxOral disorders .pptx
Oral disorders .pptx
 
SMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxSMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptx
 

Anti retroviral agents (ar vs) for midwives

  • 1. Anti-Retroviral Agents (ARVs) BY; SEYOUM GIZACHEW (B.Pharm., MSc)
  • 3. The HIV Epidemic Unfolds • Sudden outbreak in USA of opportunistic infections and cancers in homosexual men in 1981. – Pneumocystis carinii pneumonia (PCP), Kaposi’s sarcoma, and non-Hodgkins lymphoma • HIV isolated in 1984 - Luc Montanier (Pasteur Institute, Paris) and Robert Gallo (NIH, Bethesda, USA) • HIV diagnostic tests developed in 1985. • First antiretroviral drug, zidovudine, developed in 1986 • Exploding pandemic. – Has infected more than 50 million people around the world – Has killed over 22 million people. 3
  • 4. Classification of HIV • Retrovirus: single stranded RNA transcribed to double stranded DNA by reverse transcriptase • Integrates into host genome • Can lie dormant within a cell for many years, especially in resting (memory) CD4+ T4 lymphocytes • HIV type (distinguished genetically) – HIV-1 -> worldwide pandemic (~ 40 M people) – HIV-2 -> isolated in West Africa; causes AIDS much more slowly than HIV-1 but otherwise clinically similar. 4
  • 5. 5
  • 6. 6
  • 7. How HIV Enters Cells • There are three crucial steps for entry of HIV into the CD4 T cell: 1.Binding of HIV via the gp120 envelope protein to the CD4 receptor (attachment), 2.Binding to coreceptors via conformational changes to gp120, and finally 3.Fusion of virus and cell • In addition to the CD4 receptor, HIV requires coreceptors for entry into the target cell. • The two most important ones are CXCR4 and CCR5. • HIV variants mainly using CCR5 are referred to as R5 viruses; those using CXCR4 are referred to as X4 viruses. 7
  • 8. How HIV Enters Cells cont… • When the virus enters the blood, it binds a protein on its surface (gp120) to a CD4 receptor and co-receptors (CXCR4 or CCR5) on the CD4 cell. • Then gp120 shifts to expose gp41. • Once exposed, gp41 pierces the CD4 cell and pulls it in close enough to allow viral-cell fusion. • Binding of virus to cell surface results in fusion of viral envelope with cell membrane. • Viral core is released into cell cytoplasm. 8
  • 9. HIV and Cellular Receptors 9
  • 10. Viral-host Dynamics • About 1010 (10 billion) virions are produced daily • Average life-span of an HIV virion in plasma is ~6 hours • Average life-span of an HIV-infected CD4 lymphocytes is ~1.6 days • HIV can lie dormant within a cell for many years, especially in resting (memory) CD4 cells, unlike other retroviruses. • The extremely high rates of viral replication results in every possible point mutation in the viral genome arising daily. • In any given patient, the virus usually varies by 1-6% in the env gene, for example. 10
  • 11. 11
  • 12. HIV Life Cycle and Sites for Therapeutic Intervention 12
  • 13. Classes of Antiretrovirals • Fusion inhibitors – Prevents fusion of the virus into a CD4 cell by preventing conformational change needed to allow virus to enter a CD4 cell • Nucleoside reverse transcriptase inhibitors (NRTIs) or nukes (zidovudine, lamivudine) – Mimic naturally occurring nucleosides – Blocks viral DNA construction as they deceive reverse transcriptase. • Non- nucleoside reverse transcriptase inhibitors (NNRTIs) or non-nukes (Nevirapine, Efavirenz) – Bind to the reverse transcriptase enzyme • Protease inhibitors (PIs) (Indinavir, lopinavir) – Prevents cleavage of precursor protein chains. 13
  • 14. Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI’s) • • • • • • • • Lamivudine (3TC) Stavudine (d4T) Zidovudine (ZDV, AZT) Didanosine (ddI) Tenofovir (TDF) Abacavir(ABC) Emtricitabine(FTC) Zalcitabine(DDC) 14
  • 15. NRTI Mechanism of Action • NRTIs must first undergo intracellular phosphorylation to be active. • NRTIs inhibit the viral reverse transcriptase enzyme – Enzyme responsible for transcribing viral RNA into double stranded DNA • NRTIs mimic other nucleosides and are incorporated into the DNA strand • They prevent the addition of the natural nucleosides into the DNA strand • This halts the production of new virions 15
  • 16. NRTI Class Side Effects • • • • • • Nausea Headache Peripheral Neuropathy (DDC > d4T/ddI) Lipoatrophy Pancreatitis (ddI > d4T) Lactic Acidosis – d4T > ddI > ZDV – Rare with ABC, TDF, 3TC and FTC 16
  • 17. Zidovudine (ZDV) • • • • • • • • It is a deoxythymidine analog. Phosphorylated by cellular thymidine kinase. incorporated into DNA chain and terminates synthesis. well absorbed from the gut and distributed to most body tissues and fluids, including the cerebrospinal fluid The most common adverse effect is myelosuppression, resulting in macrocytic anemia. Food decreases ZDV-related nausea Pregnancy: category C Advocated for pregnant women beyond first trimester to prevent vertical transmission. 17
  • 18. Zidovudine (ZDV) cont… • Elimination: Metabolized by liver to 5’-glucuronyl zidovudine, which is renally excreted. – Reduce dose with renal or hepatic compromise: • Drug Interactions: ZDV and D4T compete for activation by thymidine kinase. • Combinations containing AZT plus d4T, is therefore pointless, since both drugs would compete for the same bases. • The combination of these drugs is antagonistic in vitro and in vivo: do not use together. 18
  • 19. Zidovudine (ZDV) cont… • Toxicity – Nausea – Bone Marrow Suppression • Anemia (fatigue) • Granulocytopenia (low platelet count) • Neutropenia (low white blood cell [neutrophils] count) – Headaches – Myalgia – Myopathy – Insomnia – Pigmentation of nail beds – Lactic acidosis 19
  • 20. Lamivudine (3TC) • A synthetic nucleoside (cytidine) analogue reverse transcriptase inhibitor • Active against HIV-1, HIV-2, and hepatitis B virus. • Phosphorylated 3 times by thymidine kinase to the active metabolite, 3TC-triphosphate. • Competes with deoxycytidine triphosphate (dCTP) for binding to reverse transcriptase and incorporation of the nucleoside analogue into viral DNA results in the termination. • 3TC-TP is a weak inhibitor of mammalian DNA polymerases α, β, and γ. • Bioavailability (F): 86%. 20
  • 21. Lamivudine (3TC) cont… • CSF Levels: 13% of serum levels (these levels have been shown to clear HIV RNA from CSF) • T1/2: 3-6 hours • Intracellular T1/2: 12 hours • Pregnancy: (Category C) – Crosses placenta. – Use in pregnancy is safe and well established, and effective. – When combined with Zidovudine, efficacy in preventing perinatal transmission is also well established. • rapid development of resistance, and a single point mutation on RT gene. 21
  • 22. Lamivudine (3TC) cont… • Intracellular T1/2 – NRTIs work in the cell, duration of action is based on intracellular half-life. • Toxicity: very rare – Headache – Occasional nausea – Lactic acidosis 22
  • 23. Tenofovir Disoproxil Fumarate (TDF) • TDF is different from nucleosides in that it has already been phosphorylated once. • T1/2: 12 to 18 hours • Intracellular T1/2: 10 to 50 hours • Pregnancy: (Category B) Crosses placenta. • Bioavailability improves with food, especially high-fat meal. • Primarily eliminated by a combination of glomerular filtration and active renal tubular secretion. • Toxicity – Headache, Nausea, diarrhea – Lactic acidosis, fatty liver – Renal insufficiency (rare) 23
  • 24. NRTI Mitochondrial Toxicity • Inhibition of mitochondrial DNA polymerase– oxidative metabolism, – ATP generation • Implicated in lactic acidosis • Other possible manifestations: – Neuropathy (d4T, ddI) – Lipoatrophy (d4T) – Pancreatitis (ddI) – Myopathy (ZDV) – Cardiomyopathy (d4T, ZDV) 24
  • 25. Facial Lipoatrophy: may be due mitochondrial toxicity. Not reversible, occur commonly with stavudine Facial Lipoatrophy: 25
  • 26. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI) • Nevirapine (NVP) • Efavirenz (EFV) • Delavirdine (DLV) • Etravirine 26
  • 27. NNRTI Mechanism of Action 27
  • 28. NNRTI Mechanism of Action cont… • NNRTIs also inhibit the viral reverse transcriptase enzyme but have a different mechanism of action compared to NRTIs. • NNRTIs bind directly to the reverse transcriptase enzyme. – Inhibit viral DNA synthesis. • Unlike the NRTI agents, NNRTIs neither compete with nucleoside triphosphates nor require phosphorylation to be active. • All are substrates for CYP3A4 and can act as inducers (nevirapine), inhibitors (delavirdine), or mixed inducers and inhibitors (efavirenz). 28
  • 29. Efavirenz • Should be taken on an empty stomach because high-fat meal increase toxicity • metabolized by CYP3A4 and CYP2B6 to inactive metabolites • It is highly bound to albumin (~ 99%) • The principal adverse effects: dizziness, drowsiness, insomnia, headache, confusion, amnesia, agitation, delusions, depression, nightmares, euphoria and Skin rash • It is both inducer and an inhibitor of CYP3A4. • Contraindicated in pregnancy (1st trimester)!! – Known to cause birth defects 29
  • 30. Nevirapine • oral bioavailability (90%) is not food-dependent • It is extensively metabolized by the CYP3A isoform • When initiating therapy, gradual dose escalation over 14 days is recommended to decrease the incidence of rash • Hepatotoxicity occurs in about 4% of patients. • a moderate inducer of CYP3A metabolism. • Rash occurs in approximately 17% of patients 30
  • 34. Protease Inhibitors (PIs) cont… • Protease inhibitors – prevent viral protease enzyme from cleaving the polyprotein precursor to viral coat protein and reduces activation of critical viral proteins/enzymes. • Thus new virons are formed, but are defective and cannot infect other cells. • Use of PIs is associated with a syndrome of redistribution and accumulation of body fat that results in central obesity to the exception of atazanavir. 34
  • 35. PI Mechanism of Action 35
  • 36. PI Mechanism of Action • Protease enzyme – responsible for cleaving (cutting up) larger polyproteins into structural proteins and reverse transcriptase enzyme. • Protease is needed to form a fully mature, functional virus that is able to replicate and produce more virus • Protease inhibitors prevent this enzyme from doing its job in the later steps of the viral life cycle 36
  • 37. PI Class Side Effects • Metabolic Disorders – Hepatotoxicities – Hyperglycemia, insulin resistance – Lipid abnormalities – Fat redistribution • Bone Disorders • GI intolerance • Drug interactions • CYP450 3A4 Inhibition – RTV > IDV = NFV = APV >SQV 37
  • 38. Lopinavir/Ritonavir • Combination in which subtherapeutic doses of ritonavir inhibit the CYP3A4-mediated metabolism of lopinavir. • Ritonavir is acting as a pharmacokinetic enhancer rather than an antiretroviral agent. • Absorption of lopinavir is enhanced with food • Lopinavir is extensively metabolized by the CYP3A isozyme. • Toxicity – Nausea, – diarrhea – Lipid abnormalities – Hyperglycemia 38
  • 39. Ritonavir • an inhibitor of HIV-1 and HIV-2 proteases • Metabolized by 3A4 > 2D6 • Ritonavir potent inhibitor of liver enzymes, especially CYP450 3A4. – CYP3A4 inhibitory properties exploited to prolong the half-life of more potent and less toxic PI agents. • Ritonavir is rarely used as a single PI anymore b/c of its side effect profile. • Instead, it is more often combined with other PIs to take advantage of its pharmacokinetic inhibitory properties. • Toxicity – GI intolerance – Tingling around mouth, bitter taste in mouth – Hepatitis, use with caution in hepatic impairment – Lipodystrophy, lipid abnormalities 39
  • 42. Fusion Inhibitors • Include: Enfuvirtide • Inhibits entry of HIV into the CD4 cell. • binds to glycoprotein gp41 (a protein on the viral membrane). – prevents a change in the shape of the membrane protein and prevents fusion of the virus and the CD4 cell membrane. – blocks entry into the cell • A synthetic 36-amino-acid peptide • Unfortunately, Enfuvirtide is only active when injected subcutaneously. • This aspect (in addition to its high cost) severely limits its use in the correctional setting. • Enfuvirtide lacks cross-resistance to the other currently approved antiretroviral drug classes. 42
  • 43. Maraviroc • First in new class of agents, CCR5 inhibitors • Approved August 6th, 2007 • Maraviroc binds to the CCR5 receptor on the membrane of human cells such as CD4 cells. – prevents the interaction of HIV-1 gp120 and human CCR5 which is necessary for entry into the cell. • Does not prevent HIV-1 entry into CXCR4-tropic or dual-tropic cells. • Indicated (in combination with other ARVs) treatment-experienced adult HIV-infected patients • Not recommended in patients who have dual/mixed tropic or CXCR4-tropic virus • Use of maraviroc should be based on treatment history and tropism assay results. 43
  • 44. Intergrase Inhibitors: Raltegravir • A pyrimidinone analog that binds and inhibits the enzyme integrase. – It inhibits strand transfer, • Bioavailability does not appear to be food-dependent • Metabolized by glucuronidation. 44
  • 45. Ethiopian ARV Guidelines (2008) - First-line Regimens Recommended ARV Regimens for Adults and Adolescents: Preferred : TDF+FTC/3TC+EFV = Triple FDC ZDV+3TC+EFV = ZDV/3TC + EFV ZDV+3TC+NVP = Triple FDC Alternatives: D4T/3TC/EFV = Double FDC (d4T/3TC) + EFV TDF/3TC/NVP D4T/3TC/NVP = Triple FDC ABC/3TC/EFV ABC/3TC/NVP ABC/3TC/ZDV = ZDV/3TC + ABC 45
  • 46. Second-line Regimens Recommended ARV Regimens for Adults and Adolescents: First-line Regimen Second-line Regimen TDF+FTC/3TC+EFV/NVP ZDV+3TC+LPV/r/ATV/r or ZDV+ABC+LPV/r/ATV/r d4T+3TC+EFV/NVP TDF+3TC+/-ZDV+LPV/r/ATV/r or ABC+ ddI+ LPV/r/ATV/r ABC + 3TC + ZDV EFV/NVP + LPV/r/ATV/r 46
  • 47. PMTCT ARVs decrease risk of MTCT by two mechanisms: 1. By reducing the viral load in the mother ARVs block viral replication →↓Viral load in the body→↑CD4cells →Improved maternal immunity 2. By preventing the virus from fixing itself in the infant 47
  • 48. Table: Three options for PMTCT programmes (WHO 2012) a Recommended in WHO 2010 PMTCT guidelines b True only for EFV-based first-line ART; NVP-based ART not recommended for prophylaxis (CD4 >350) c Formal recommendations for Option B+ have not been made, but presumably ART would start at 48 diagnosis.
  • 49. Reading Assignments • Chemotherapy of protozoal infections • Antifungals • Anthelmintics 49